Tech Company Financing Transactions
Imvax Funding Round
On 7/20/2020, Imvax raised $112 million in Series C funding from HP Wild Holding AG, Invus and Magnetar Capital Return.
Transaction Overview
Company Name
Announced On
7/20/2020
Transaction Type
Venture Equity
Amount
$112,000,000
Round
Series C
Investors
Proceeds Purpose
The financing will enable Imvax to continue clinical development of lead product candidate IGV-001 for treatment of GBM through Phase 2. IGV-001 is a autologous tumor vaccine made from patients' tumor cells combined with an antisense molecule to affect a personalized immune response.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
601 Walnut St. 440 W
Philadelphia, PA 19106
USA
Philadelphia, PA 19106
USA
Phone
Website
Email Address
Overview
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company's lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Furey
Chief Financial Officer
Arthur Howe
Chief Medical Officer
David Andrews
Chief Scientific Officer
Mark Exley
VP - Regulatory Affairs
Catherine Kessler
Browse more venture capital transactions:
Prev: 7/17/2020: Qualio venture capital transaction
Next: 7/20/2020: Cityblock Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs